Hikma Pharmaceuticals Given Overweight Rating at JPMorgan Chase (HIK)
Hikma Pharmaceuticals (LON: HIK)‘s stock had its “overweight” rating restated by equities researchers at JPMorgan Chase in a report issued on Monday. They currently have a $16.54 (1100 GBX) target price on the stock.
Hikma Pharmaceuticals opened at 924.50 on Monday. Hikma Pharmaceuticals has a 52-week low of GBX 598.50 and a 52-week high of GBX 888.00. The stock’s 50-day moving average is currently GBX 728.8. The company’s market cap is £1.812 billion.
Several other analysts have also recently commented on the stock. Analysts at UBS AG reiterated a “sell” rating on shares of Hikma Pharmaceuticals in a research note to investors on Monday. They now have a $11.35 price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research note to investors on Friday. They now have a $13.52 price target on the stock. Finally, analysts at Panmure Gordon raised their price target on shares of Hikma Pharmaceuticals from $14.10 to $15.16 in a research note to investors on Friday. They now have a “buy” rating on the stock.
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.